Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. At Glaukos, our focus is to develop and lead the global ophthalmic market with novel therapies that advance the existing standard of care, and enrich the lives and treatment alternatives for patients worldwide. Glaukos is transforming the treatment of chronic eye diseases with novel therapies that provide sustainable solutions to important clinical needs.
Find locations served, office locations
- Business Type:
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
- Year Founded:
We were the first company to bring to market Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure that revolutionized the treatment and management of glaucoma. In 2012, we launched our first MIGS device—the iStent®—in the United States, followed by our next-generation iStent inject® device in September 2018 and iStent inject® W in September 2020.
In November 2019, Glaukos acquired Avedro, maker of the first and only FDA-approved cross-linking technology for progressive keratoconus. And we continue to seek to leverage our platform technologies to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies for glaucoma, corneal health, and retinal diseases.
Our company completed an initial public offering in June of 2015, and our shares are traded on the New York Stock Exchange under the ticker symbol “GKOS”. Our global headquarters is located in San Clemente, California, and we have additional locations in 9 regions around the world.
Our mission is to transform the treatment of chronic eye diseases with novel therapies that provide sustainable solutions to important clinical needs.
Our History of Firsts
Since our inception, every milestone has pushed us to the next, enabling us to transform the future of eye care.
Glaukos is founded
The first human implant of micro-bypass glaucoma stent is performed
Glaukos receives Category III CPT code to describe insertion of a flow device into the trabecular meshwork of the eye
Glaukos secures 100% Medicare coverage for the iStent® procedure
Glaukos completes initial public offering
Glaukos expands into 17 countries with direct sales operations
Glaukos acquires Avedro, establishing the cornerstone of a new corneal health franchise
Glaukos acquires DOSE Medical, establishing a new R&D retinal program
Glaukos enters licensing agreement with Intratus for a non-invasive, cream-based drug delivery platform
The first trabecular micro-bypass glaucoma stent is developed
Landmark trial evaluating iStent® in conjunction with cataract surgery begins
iStent® is approved by the FDA in combination with cataract surgery
Glaukos establishes a direct sales organization in the United States for iStent®
Glaukos launches iStent inject® in Germany
Glaukos establishes a direct sales organization in Germany
iStent® is approved in Japan
iStent® launches in Australia and Canada
iStent inject® is approved by the FDA in combination with cataract surgery; US commercial launch
Glaukos enters pharmaceutical development agreement with D. Western, a preeminent research organization
Glaukos exceeds 700,000 iStent® devices implanted
iStent inject® W is launched
The iLink™ corneal cross-linking procedure is introduced to the Glaukos family
Glaukos completes convertible debt financing
Glaukos issues inaugural sustainability report